
Jonathan Block
Managing Editor, Sectors at Seeking Alpha
Managing Editor, Sectors and Senior Health Care News Editor at Seeking Alpha. MPH from CUNY Graduate School of Public Health. All opinions are mine.
Articles
-
1 week ago |
seekingalpha.com | Jonathan Block
UroGen Pharma (NASDAQ:URGN) closed Friday up ~43%, a week before the U.S. FDA is set to act on its NDA for UGN-102 (mitomycin), a treatment for a type of bladder cancer. It is not immediately clear what caused the surge today.
-
1 week ago |
seekingalpha.com | Jonathan Block
Phathom Pharmaceuticals has shot up ~125% in Friday trading after the U.S. FDA granted their Citizen Petition regarding the expiration date of new chemical entity exclusivity for their drug Voquezna (vonoprazan). Trading in the stock was briefly halted from 1211p-1221p
-
1 week ago |
seekingalpha.com | Jonathan Block
-
1 week ago |
seekingalpha.com | Jonathan Block
-
1 week ago |
seekingalpha.com | Jonathan Block
Sarepta Therapeutics, Inc. Ultragenyx Pharmaceutical Inc.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 449
- Tweets
- 872
- DMs Open
- No

Yet another interesting development involving @CassavaSciences #Alzheimers #CUNY Interesting that $SAVA shares up 12% in Tuesday afternoon trading. https://t.co/cHMREionxh

Exciting news for @GEHealthCare and @VUMCDiscoveries, and promising for using #ai to improve health outcomes for #cancer patients. https://t.co/3necZyZqtn

Antibody-drug conjugates, a relatively new type of cancer treatment, are poised to boost the bottom lines on several pharma and biotech companies. https://t.co/BQPaw7U4Ny